These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 2407093)

  • 1. Placement of moricizine in the selection of antiarrhythmic drug therapy.
    Morganroth J
    Am J Cardiol; 1990 Feb; 65(8):65D-67D; discussion 68D-71D. PubMed ID: 2407093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moricizine. A review of its pharmacological properties, and therapeutic efficacy in cardiac arrhythmias.
    Fitton A; Buckley MT
    Drugs; 1990 Jul; 40(1):138-67. PubMed ID: 2202581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic drug therapy for congestive heart failure with focus on moricizine.
    Podrid PJ; Beau SL
    Am J Cardiol; 1990 Feb; 65(8):56D-64D; discussion 68D-71D. PubMed ID: 2407092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Moricizine: a novel antiarrhythmic agent.
    Carnes CA; Coyle JD
    DICP; 1990; 24(7-8):745-53. PubMed ID: 2197817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of moricizine in patients with congestive heart failure: a summary of the experience in the United States.
    Pratt CM; Podrid P; Greatrix B; Borland RM; Mahler S
    Am Heart J; 1990 Jan; 119(1):1-7. PubMed ID: 1688682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural history of potentially lethal ventricular arrhythmias in patients treated with long-term antiarrhythmic drug therapy.
    Kennedy HL; Sprague MK; Homan SM; Seiler SM; Wiens RD; Janosik DL; Redd RM; Buckingham TA
    Am J Cardiol; 1989 Dec; 64(19):1289-97. PubMed ID: 2686388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proarrhythmic potential of moricizine: strengths and limitations of a data base analysis.
    Pratt CM
    Am J Cardiol; 1990 Feb; 65(8):51D-55D; discussion 68D-71D. PubMed ID: 1689536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical development of moricizine as an antiarrhythmic agent.
    Mahler SA; Borland RM
    Am J Cardiol; 1990 Feb; 65(8):11D-14D; discussion 68D-71D. PubMed ID: 2407088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ethmozine (moricizine HCl) therapy for complex ventricular arrhythmias.
    Hession MJ; Lampert S; Podrid PJ; Lown B
    Am J Cardiol; 1987 Oct; 60(11):59F-66F. PubMed ID: 3310587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indications for antiarrhythmic suppression of ventricular arrhythmias: a definition of life-threatening ventricular arrhythmias.
    Morganroth J
    Am J Cardiol; 1993 Aug; 72(4):3A-7A. PubMed ID: 8346724
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiarrhythmic effects of beta-adrenergic blocking agents in benign or potentially lethal ventricular arrhythmias.
    Morganroth J
    Am J Cardiol; 1987 Aug; 60(6):10D-14D. PubMed ID: 2888297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessment of benefit-risk ratio and treatment algorithms for antiarrhythmic drug therapy after the cardiac arrhythmia suppression trial.
    Anderson JL
    J Clin Pharmacol; 1990 Nov; 30(11):981-9. PubMed ID: 2122984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparisons of efficacy and tolerance of moricizine with other antiarrhythmic agents in the treatment of chronic ventricular arrhythmias.
    Anderson JL
    Am J Cardiol; 1990 Feb; 65(8):32D-40D. PubMed ID: 2106254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerance of Ethmozine (moricizine HCl) in placebo-controlled trials.
    Morganroth J; Pratt CM; Kennedy HL; Singh SN; Platt ML; Baker BJ; Mason DT
    Am J Cardiol; 1987 Oct; 60(11):48F-51F. PubMed ID: 3310585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS.
    Cardiac Arrhythmia Pilot Study (CAPS) Investigators
    Am J Cardiol; 1988 Mar; 61(8):501-9. PubMed ID: 2894169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Class IB antiarrhythmic drugs: tocainide, mexiletine, and moricizine.
    Snyder DW
    J La State Med Soc; 1989 May; 141(5):21-5. PubMed ID: 2499645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Noncardiac adverse effects and organ toxicity of moricizine during short- and long-term studies.
    Kennedy HL
    Am J Cardiol; 1990 Feb; 65(8):47D-50D. PubMed ID: 2407091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose effect of moricizine on suppression of ventricular arrhythmias.
    Morganroth J
    Am J Cardiol; 1990 Feb; 65(8):26D-31D; discussion 68D-71D. PubMed ID: 1689534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Moricizine: pharmacodynamic, pharmacokinetic, and therapeutic profile of a new antiarrhythmic.
    Vanerio G; Maloney JD
    Cleve Clin J Med; 1992; 59(1):79-86. PubMed ID: 1551218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.